Equities research analysts predict that Chimerix Inc (NASDAQ:CMRX) will report $850,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Chimerix’s earnings. The highest sales estimate is $1.65 million and the lowest is $370,000.00. Chimerix posted sales of $1.84 million during the same quarter last year, which suggests a negative year-over-year growth rate of 53.8%. The firm is expected to announce its next earnings report on Thursday, March 7th.
On average, analysts expect that Chimerix will report full year sales of $3.03 million for the current fiscal year, with estimates ranging from $2.35 million to $4.00 million. For the next year, analysts forecast that the business will report sales of $10.57 million, with estimates ranging from $2.72 million to $25.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Chimerix.
A number of equities analysts recently weighed in on the company. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Cowen reaffirmed a “hold” rating and set a $6.00 target price on shares of Chimerix in a research note on Thursday, October 18th. HC Wainwright reaffirmed a “buy” rating on shares of Chimerix in a research note on Wednesday, February 6th. Finally, ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Chimerix presently has a consensus rating of “Buy” and an average target price of $6.17.
Shares of CMRX opened at $2.12 on Thursday. The stock has a market capitalization of $108.04 million, a P/E ratio of -1.40 and a beta of 1.39. Chimerix has a 1-year low of $2.08 and a 1-year high of $5.94.
Large investors have recently added to or reduced their stakes in the business. Opaleye Management Inc. grew its stake in Chimerix by 3.0% during the 3rd quarter. Opaleye Management Inc. now owns 1,185,000 shares of the biopharmaceutical company’s stock valued at $4,609,000 after acquiring an additional 35,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Chimerix by 3.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,556,524 shares of the biopharmaceutical company’s stock valued at $9,945,000 after buying an additional 74,910 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Chimerix by 6.2% during the 3rd quarter. BlackRock Inc. now owns 3,711,445 shares of the biopharmaceutical company’s stock valued at $14,439,000 after buying an additional 215,268 shares during the last quarter. Leisure Capital Management acquired a new stake in shares of Chimerix during the 3rd quarter valued at about $108,000. Finally, Vanguard Group Inc lifted its holdings in shares of Chimerix by 6.4% during the 3rd quarter. Vanguard Group Inc now owns 2,115,044 shares of the biopharmaceutical company’s stock valued at $8,228,000 after buying an additional 126,847 shares during the last quarter. 73.10% of the stock is currently owned by institutional investors.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Further Reading: What is an investor looking for in an SEC filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.